pharmaphorum

FEBRUARY 21, 2022

It’s a key moment for the two companies, as expansion into HER2-low breast cancer has been held up as a key requirement for Enhertu (trastuzumab deruxtecan) if it is to achieve its multibillion-dollar sales expectations. billion to Daiichi Sankyo if all the ADC’s development and sales objectives are achieved.

Trials 132

Trials Sales Hormones Drugs 132

XTalks

MARCH 18, 2025

Incytes recent announcement on the topline results from two Phase III clinical trials of povorcitinib in patients with hidradenitis suppurativa has stirred both hope and caution in the market. These promising figures had set high expectations for subsequent trials. The other Phase III trial, STOP-HS2, showed a 42.3% for placebo.

Trials 59

Trials Clinical Trials Clinical Trials Hormones 59

pharmaphorum

DECEMBER 3, 2021

Just released results from the ARASENS trial show that adding Nubeqa (darolutamide) to docetaxel chemotherapy and androgen deprivation therapy (ADT) to switch off testosterone production helps men with castration-sensitive prostate cancer (CSPC).

Trials 107

Trials Sales Hormones Drugs 107

XTalks

MARCH 1, 2021

Anti-inflammatory drugs like Restasis and Xiidra are popular treatment options for the condition, but will the emergence of mask-associated dry eye bolster their sales? But if you thought the growing number of patients presenting with mask-associated dry eye would mean higher sales for Restasis, think again.

Sales 119

Sales Drugs Life Science Containment 119

pharmaphorum

MAY 27, 2021

It is thought that around five million women in the US have uterine fibroids that cause symptoms, with two-thirds of them inadequately treated with current drugs – generally off-label oral contraceptives or injectable gonadotropin releasing hormone (GnRH) agonists like leuprolide acetate or goserelin acetate.

Hormones 98

Hormones Sales Marketing Drugs 98

pharmaphorum

APRIL 25, 2022

Roche revealed in its first-quarter results statement that giredestrant missed the mark in the phase 2 acelERA trial in advanced breast cancer, in what appears to be another blow to the emerging oral selective oestrogen receptor degrader (SERD) class. The post Roche’s oral SERD giredestrant fails breast cancer trial appeared first on.

Trials 69

Trials Hormones HR Sales 69

XTalks

JANUARY 29, 2025

Related: Eli Lillys Zepbound Approved as First Treatment for Obstructive Sleep Apnea The commercial describes Zepbounds mechanism of action as a dual receptor against that works by activating two naturally occurring hormone receptors in [the] body [GLP-1 and GIP-1]. Its changing how much weight I lose, up to 48 lbs, he says.

FDA Approval 71

FDA Approval Drugs Hormones Marketing 71

pharmaphorum

AUGUST 30, 2022

Neurocrine Biosciences has featured on lists of potential takeover candidates for years, but has now taken the lead on a buyout of UK biotech Diurnal that if consummated will extend its therapeutic focus further into hormonal disorders. In July, Diurnal reported product sales of around £2.3 Shares in the UK firm had leaped 132% to 26.1

Hormones 105

Hormones Sales Clinical Trials Clinical Trials 105

pharmaphorum

SEPTEMBER 15, 2021

If approved, linzagolix will be the only drug in the class with a dosing regimen intended for women with uterine fibroids who cannot or do not want to take hormone therapy, as well as options for those women happy to do so, according to ObsEva.

Hormones 98

Hormones Drugs FDA Approval Sales 98

pharmaphorum

AUGUST 16, 2022

The US regulator has started a priority review of Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone as a first-line treatment for metastatic castration-resistant prostate cancer (mCRPC) based on the results of the PROpel trial. months and 16.6 months, respectively. billion in the first half of this year.

Hormones 111

Hormones Gene Sales Trials 111

pharmaphorum

OCTOBER 11, 2020

Pfizer already makes big revenues from its breast cancer drug Ibrance, but a late-stage trial failure has set back its hopes of even loftier sales – and set up a challenge from Eli Lilly’s rival drug Verzenio. That study isn’t due to read out until 2026, according to the ClinicalTrials.gov database.

Trials 52

Trials HR Hormones Drugs 52

pharmaphorum

AUGUST 11, 2020

At the beginning of this year, KaNDy completed a phase 2b trial of its first-in-class drug NT-814, showing activity against symptoms of the menopause such as hot flashes and night sweats. A phase 3 trial is expected to begin in 2021 and the company says that the compound could generate peak sales of more than a billion euros globally.

Drugs 98

Drugs Hormones Marketing Trials 98

XTalks

NOVEMBER 9, 2022

Lilly is also working towards an obesity treatment form of tirzepatide, with trials currently underway to evaluate its weight loss effects. Since Mounjaro’s May US Food and Drug Administration (FDA) approval, sales of the drug have skyrocketed beyond initial expectations owing to patient demand and a temporary shortage of Novo’s Ozempic.

Insulin 98

Insulin Hormones FDA Approval Sales 98

pharmaphorum

AUGUST 15, 2022

In the space of a couple of months, Gilead Sciences’ Trodelvy impact on overall survival (OS) in the TROPICs-02 trial in advanced breast cancer has gone from a trend to a statistically significant improvement, raising its chances of approval in a new indication.

HR 90

HR Hormones Sales Antibody 90

pharmaphorum

MARCH 8, 2021

The cost-effectiveness agency is assessing use of Lynparza (olaparib) in patients with tumours that carry BRCA1 or BRCA2 mutations who have previously been treated with the hormone therapies abiraterone and enzalutamide but have relapsed. The post NICE says no to AZ’s Lynparza for prostate cancer appeared first on.

Hormones 98

Hormones Marketing Trials DNA 98

Pharmaceutical Technology

JUNE 5, 2023

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Rezvilutamide is indicated for the treatment of metastatic hormone sensitive prostate cancer. Rezvilutamide overview Rezvilutamide is an antineoplastic agent.

Medicine 100

Medicine Hormones Production Clinical Trials 100

Pharmaceutical Technology

JUNE 5, 2023

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Rezvilutamide is indicated for the treatment of metastatic hormone sensitive prostate cancer. Rezvilutamide overview Rezvilutamide is an antineoplastic agent.

Medicine 100

Medicine Hormones Production Clinical Trials 100

pharmaphorum

MARCH 10, 2022

Bayer has filed for approval to extend the use of its prostate cancer therapy Nubeqa as it tries to achieve labelling parity with rival drugs from Pfizer/Astellas and Johnson & Jonson, and fulfil its aim of €3 billion in peak sales for the drug.

Hormones 81

Hormones Sales Drugs Marketing 81

Pharmaceutical Technology

JUNE 6, 2023

Ecubectedin is a small molecule commercialized by Pharma Mar, with a leading Phase II program in Hormone Sensitive Breast Cancer. According to Globaldata, it is involved in 5 clinical trials, which are ongoing. It is administered through intravenous route. The drug candidate is a marine-derived compound.

Hormones 100

Hormones In-Vitro Genotype Bacteria 100

XTalks

NOVEMBER 3, 2022

Mounjaro has thus taken off stronger than expected, surpassing Wall Street sales forecasts during the third quarter. Mounjaro was approved this summer as a Type 2 diabetes treatment and is the first diabetes drug with dual action, targeting two hormones involved in insulin production and appetite (GIP and GLP-1).

Sales 98

Sales FDA Approval Production Insulin 98

XTalks

MARCH 8, 2021

Eli Lilly (NASDAQ: LLY ) reported late last week that its investigational diabetes injection, tirzepatide, demonstrated superiority to Novo Nordisk’s (NASDAQ: NVO ) ozempic (semaglutide) in a Phase III trial. billion in sales last year, making it the company’s biggest revenue generator in 2020. SURPASS-2 Clinical Trial.

Insulin 98

Insulin Hormones Clinical Trials Clinical Trials 98

XTalks

FEBRUARY 8, 2024

The top 15 diabetes drugs in 2023, according to 2022 sales data, reflect the current state of diabetes management and hint at the evolving needs and trends within this critical area of healthcare. Read on to learn more about the top 15 diabetes drugs in 2023, based on 2022 sales statistics. mL subcutaneous solution (2 mg/1.5

Sales 52

Sales Insulin FDA Approval Drugs 52

XTalks

JANUARY 23, 2024

Pediatric growth hormone deficiency (PGHD) is one such condition, affecting a child’s growth and development. This rare endocrine disorder, characterized by inadequate secretion of growth hormone from the pituitary gland, has profound impacts on physical and sometimes cognitive development.

Development 72

Development Hormones Drugs Trials 72

XTalks

FEBRUARY 5, 2024

The top 40 best-selling oncology drugs in 2023, informed by 2022 sales statistics, mark significant milestones in cancer treatment and research. Read on to learn more about the top 40 best-selling oncology drugs in 2023, based on 2022 sales data. Price of Revlimid: A supply of 28 oral 2.5 mg capsules is $24,576.

FDA Approval 101

FDA Approval Drugs Sales Development 101

pharmaphorum

JUNE 4, 2021

Novartis’ big investment in radiopharmaceuticals for cancer seems to have paid off, after lead candidate 177Lu-PSMA-617 helped men with advanced prostate cancer and few treatment options live longer in a phase 3 trial. The drug made $445 million in sales last year. billion takeover of Endocyte in 2018. months, compared to 3.4

Hormones 88

Hormones Licensing Licensing Drugs 88

pharmaphorum

AUGUST 8, 2022

The US regulator has approved Nubeqa (darolutamide) in combination with docetaxel chemotherapy for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC), adding to its earlier indication in non-metastatic castration-resistant prostate cancer (nmCRPC). billion) blockbuster.

Sales 59

Sales Hormones Marketing FDA Approval 59

Delveinsight

DECEMBER 29, 2020

Relugolix is a once-daily, oral gonadotropin-release hormone (GnRH) receptor antagonist. billion – a deal that is split into upfront payments, and sales and regulatory milestone payments. Audentes Therapeutics’ ASPIRO Trial Free to Proceed. mg and norethindrone acetate (0.5 mg) in the US and Canada. The post A USD 4.2

Trials 52

Trials Drugs Hormones Radiology 52

pharmaphorum

SEPTEMBER 22, 2022

The company said this morning that US sales growth is its main priority, and that it will be led in the near-term by “high-value” new drugs Kisqali (ribociclib), iptacopan, Pluvicto (lutetium Lu 177 vipivotide tetraxetan), remibrutinib, and Scemblix (asciminib). billion by 2024. Results are due next year.

Sales 52

Sales Trials Hormones Clinical Trials 52

Pharmaceutical Technology

FEBRUARY 18, 2023

According to Globaldata, it is involved in 24 clinical trials, of which 19 were completed, 2 are ongoing, 1 is planned, and 2 were terminated. Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV).

Hormones 100

Hormones Development Production Clinical Trials 100

XTalks

AUGUST 2, 2023

Most of the company’s revenue comes from the manufacture and sale of biopharmaceutical products. 5) Ibrance (palbociclib) Ibrance is a chemotherapy drug indicated for hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. billion in pharmaceutical sales from 2021.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

MAY 14, 2021

Description: Acne No More is a clinically proven 5-step multi-dimensional clear skin system that has been polished and perfected over 13 years of research, trial, and error. CLICKBANK is a registered trademark of Click Sales, Inc., The website’s content and the product for sale. a Delaware. corporation located at 1444 S.

Production 52

Production Hormones Sales Licensing 52

pharmaphorum

SEPTEMBER 21, 2022

Takeda has decided that there is a future for its aurora kinase A inhibitor alisertib after it failed a phase 3 trial in lymphoma – but the company won’t be taking the drug forward itself. Takeda is also in line for just over $287 million in potential milestone payments, plus royalties on net sales if it reaches the market.

Drugs 64

Drugs HR Licensing Licensing 64

XTalks

JUNE 20, 2022

TTR is made in the liver and is involved in carrying the thyroid hormone thyroxine (T4) and retinol (vitamin A) to the liver. At the same time, investors’ eyes are on the company’s Phase III APOLLO-B trial for Onpattro in this heart disease indication. billion in global sales by 2026.

FDA Approval 98

FDA Approval Protein Genetics RNA 98

XTalks

NOVEMBER 20, 2023

AstraZeneca has won its first-in-class approval for its AKT inhibitor Truqap (capivasertib) in combination with Faslodex (fulvestrant) for treating patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. billion to $1.28

HR 98

HR FDA Approval Gene Trials 98

pharmaphorum

OCTOBER 14, 2022

The EU decision follows a green light from the FDA for longer-duration use of Mirena – an intrauterine device (IUD) that also delivers the hormone levonorgestrel – in August. Approximately 17% of women of reproductive age (around 160 million worldwide) use intrauterine contraception, including hormone-releasing products.

Hormones 59

Hormones Compliance Clinical Trials Clinical Trials 59

pharmaphorum

MAY 6, 2022

The suspension affects sites at Ivrea in Italy and Millburn in New Jersey, and will affect both commercial and clinical trial supplies of its Lutathera for neuroendocrine tumours (NET) and recently-approved prostate cancer therapy Pluvicto. “Health authorities have been informed and will receive additional updates as they are available.”

Manufacturing 52

Manufacturing Hormones Clinical Trials Clinical Trials 52

pharmaphorum

JULY 13, 2022

It is currently in a phase 2 trial for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), said Merck. “Targeting CYP11A1 provides a compelling approach to suppressing the production of steroid hormones,” said Dean Li, president of Merck Research Laboratories.

Licensing 52

Licensing Licensing Hormones Production 52